

# A Randomized Trial of Internet and Telephone Treatment for Smoking Cessation

Amanda L. Graham, PhD; Nathan K. Cobb, MD; George D. Papandonatos, PhD; Jose L. Moreno, MA; Hakmook Kang, MS; David G. Tinkelman, MD; Beth C. Bock, PhD; Raymond S. Niaura, PhD; David B. Abrams, PhD

**Background:** This study aimed to determine the relative effect of Internet and Internet plus telephone treatment for smoking cessation on smoking abstinence among US adults. A priori hypotheses were that Internet enhanced with tailored content and social support would outperform basic Internet (BI) and that enhanced Internet (EI) plus proactive telephone counseling would outperform the other conditions.

**Methods:** The Quit Using Internet and Telephone Treatment (iQUITT) study used a 3-group randomized controlled design comparing BI, EI, and EI and telephone combined (EI+P). The trial was conducted from March 8, 2005, through November 30, 2008. Current adult smokers in the United States who smoked 5 or more cigarettes per day were recruited via search engines. Characteristics of the 2005 participants include mean (SD) age of 35.9 (10.8) years, 51.1% women, and 86.5% white. The follow-up assessment rate at 18 months was 68.2%. The

main outcome measure was 30-day point prevalence abstinence measured at 3, 6, 12, and 18 months after randomization using intent-to-treat analysis.

**Results:** At 18 months, the 30-day multiple point prevalence abstinence rate across all follow-up intervals was 3.5% (BI), 4.5% (EI), and 7.7% (EI+P), with EI+P significantly outperforming BI and EI. At 18 months, 30-day single point prevalence abstinence rates were 19.0% (BI), 17.4% (EI), and 19.6% (EI+P) and did not differ among the groups.

**Conclusions:** Combined Internet and telephone treatment outperforms static and dynamic Internet interventions.

**Trial Registration:** clinicaltrials.gov Identifier: NCT00282009

*Arch Intern Med.* 2011;171(1):46-53

**Author Affiliations:** Schroeder Institute for Tobacco Research and Policy Studies, American Legacy Foundation (Drs Graham, Cobb, Niaura, and Abrams and Mr Moreno), and Georgetown University Medical Center/Lombardi Comprehensive Cancer Center (Drs Graham and Cobb), Washington, DC; Center for Statistical Sciences, Brown University (Dr Papandonatos and Mr Kang), and Centers for Behavioral and Preventive Medicine, Brown University/The Miriam Hospital (Dr Bock), Providence, Rhode Island; National Jewish Health, Denver, Colorado (Dr Tinkelman); and Department of Health, Behavior, and Society, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Drs Niaura and Abrams).

**A**CCCELERATING THE REDUCTION in the population prevalence of smoking will require innovative approaches to reach and treat current smokers.<sup>1</sup> The Internet has the potential to reach millions of smokers per year with evidence-based cessation treatment.<sup>2,3</sup> The key components of recommended treatment, namely, problem solving and skills training, Food and Drug Administration–approved pharmacotherapy, and social support,<sup>4</sup> can be provided efficiently, proactively, and in real

## See Invited Commentary at end of article

time and can be sustained for as long as the user desires. Few large-scale, rigorous trials of Web-based cessation interventions have been conducted<sup>5-10</sup> and they have yielded mixed results, with abstinence rates ranging from 7% at 3 months through 21% at 12 months. Studies have varied in rigor on several dimensions, including design, sample size, sample selection and bias, intervention content, length

of follow-up, attrition rate, and outcome metrics, but recent meta-analyses provide evidence of effectiveness.<sup>11,12</sup>

## See also page 39

Because combined treatments are associated with better outcomes,<sup>4</sup> adding proactive telephone counseling to Internet treatment may further improve the effect on the population. National guidelines for treating tobacco use and dependence recommend that health care professionals and health care provision systems promote telephone quitline use.<sup>4</sup> Available throughout the United States, telephone counseling significantly increases abstinence rates compared with minimal or no counseling, with a point prevalence abstinence (PPA) rate of 12.7% reported at 6 months in a 2008 meta-analysis.<sup>4</sup> Combined treatment leverages the strengths of individualized telephone counseling with the sustained support available around the clock via the Internet<sup>13</sup> and is increasingly being offered to consumers. Approximately half of all telephone quitlines provide cessation services via the Internet,<sup>14</sup> and numerous health plans and employers provide com-

bined cessation treatment. As stated by Croyle,<sup>15(p72)</sup> “stand-alone quitlines are already a fading anachronism” but evidence concerning combined treatment remains limited. One large observational study<sup>13</sup> reported a 30-day abstinence rate of 21% at 6 months among 11 143 participants. Despite the widespread availability of combined Internet and telephone treatment for smoking cessation, to our knowledge there have been no randomized trials to evaluate its efficacy.

Evaluating the effectiveness of Internet only and combined Internet and telephone interventions has major implications for research, practice, and policy. Market demand is driving provision of combined smoking cessation treatments without empirical evidence.<sup>15</sup> If effective, Internet or combined Internet and telephone treatment could play a central role in the efficient implementation of tobacco control programs.<sup>1,16</sup> This article presents the primary outcomes of the Quit Using Internet and Telephone Treatment (iQUITT) study, a large-scale, 3-arm randomized controlled trial that evaluated the comparative effectiveness of enhanced Internet (EI) and Internet in conjunction with proactive telephone counseling (EI+P) against a basic Internet (BI) comparison condition. A priori hypotheses were that EI and EI+P would produce higher quit rates compared with BI and that EI+P would outperform EI.

## METHODS

### PARTICIPANTS

The trial was conducted from March 8, 2005, through November 30, 2008. Participants were 2005 current smokers recruited from March 8, 2005, through May 23, 2007. Described previously,<sup>17</sup> active user interception sampling was used to recruit US adults who used the terms *quit(ting) smoking*, *stop(ping) smoking*, or *smoking* in a major Internet search engine and who clicked on a link to the cessation treatment Web site being evaluated ([www.quitnet.com](http://www.quitnet.com)). Preliminary eligibility screening was conducted online. Eligibility criteria included US residence, current smoking of 5 or more cigarettes per day, age of 18 years or older, and no prior use of the QuitNet Web site as confirmed by the absence of a tracking cookie. Eligible participants provided online informed consent and personal contact information. A research assistant contacted participants by telephone to confirm eligibility, obtain informed consent, and administer the baseline assessment. Randomization was conducted via random numbers table and was stratified by sex and baseline motivation to quit. After randomization, participants were sent an automated e-mail that provided a copy of the study consent form, a Web link (URL) for their assigned Internet treatment condition (ie, BI or EI), and instructions regarding telephone counseling. A unique identifier embedded in the URL was used for tracking Web site use.

### DESIGN

The protocol received human subject protections approval from the Georgetown University institutional review board. All participants provided electronic and audiotaped informed consent. After the baseline assessment, participants were randomly assigned as follows: 679 to BI, 651 to EI, and 675 to EI+P. Participants completed follow-up assessments of smoking abstinence and psychosocial measures at 3, 6, 12, and 18 months

after randomization and were paid \$15 to \$25 for completing each assessment. The BI and EI Web sites required participants to authenticate (log in) using a username and password they chose at registration.

### TREATMENT CONDITIONS

Participants randomized to EI were given free, 6-month access to the full version of QuitNet.com, an interactive, commercial cessation Web site that provides evidence-based cessation treatment in accordance with national guidelines.<sup>4</sup> QuitNet provides (1) advice to quit; (2) assistance in setting a quit date; (3) assessment of motivation, smoking history, demographics, and nicotine dependence; (4) individually tailored information based on the assessment; (5) problem solving and skills training content; (6) tailored assistance in using Food and Drug Administration–approved pharmacotherapies; and (7) social support within its large online social network.<sup>18</sup> The Web site remained consistent throughout the study period, with minimal upgrades or enhancements.

Participants randomized to EI+P received 6-month free access to the full QuitNet Web site and proactive telephone counseling from trained, experienced counselors using the evidence-based and field-tested protocol of National Jewish Health. National Jewish Health is a nonprofit academic medical center located in Denver, Colorado, that has provided telephone counseling services to state quit lines, health plans, and employer groups since 2002 as part of its suite of wellness products. Counselors who participated in this project were part of a larger call center quit-line operation at National Jewish Health and followed the same counseling and quality monitoring protocols. QuitNet and telephone counseling were seamlessly integrated to create a comprehensive program. Participants were offered 5 calls in a relapse-sensitive schedule,<sup>19</sup> providing intensive support during the first 30 days after a quit attempt when smokers are at highest risk of relapse.<sup>20</sup> The goals of each telephone contact were to establish a supportive working relationship with the participant and to provide information and assist the participant in skill building to prepare for a quit attempt or to prevent relapse after a quit attempt. Counselors also prompted and reinforced use of QuitNet during each call. Counselors had real-time access to summary data regarding a participant's engagement on QuitNet through a system that facilitated the reciprocal exchange of data between telephone counselors and the Web site. Utilization metrics available to counselors included the date and time of a participant's registration on QuitNet, number of visits, number of posts in the online community, number of buddies, date of last login, and the use status of the enhanced (ie, individually tailored content and social network) components of the Web site. Telephone counselors incorporated this information into the counseling process and made specific recommendations about use of the Web site based on an individual's history. Counselors also sent individually tailored e-mails to the participant after completion of the counseling call to reinforce important elements of the discussion.

Participants randomized to BI were given 6-month free access to a static, information-only comparison condition<sup>21</sup> composed of the content on QuitNet. This content included general cessation information, cessation pharmacotherapy information and directions for use, a directory of national cessation programs, and a database of frequently asked questions accumulated during the 10-year lifespan of QuitNet. Where possible, the language, graphics, and formatting of QuitNet were retained in the BI condition for usability and credibility. To allow for the examination of theory-driven hypotheses about mediators of treatment outcome, the interactive and individually tailored features of QuitNet and its social network were not available in BI.

## ASSESSMENT PROTOCOL

The baseline telephone assessment measured demographics, smoking variables, and relevant psychosocial characteristics (ie, stress, depression, and social support). Age, race, ethnicity, sex, marital status, household income, education, and employment status were assessed using standard items from the Behavioral Risk Factor Surveillance System.<sup>22</sup> Smoking variables included age of first smoking experience, age at onset of daily smoking, the number of intentional 24-hour quit attempts in the past year, desire to quit (1-10), confidence in quitting (1-10), motivation to quit,<sup>23</sup> daily smoking rate, and the Fagerström Test for Nicotine Dependence score.<sup>24</sup> Participants completed the Perceived Stress Scale,<sup>25,26</sup> the Center for Epidemiologic Studies–Depression Scale,<sup>27</sup> a modified version of the Partner Interaction Questionnaire,<sup>28</sup> and the Social Network Index.<sup>29,30</sup> Whenever possible, brief measures with known psychometric properties were selected to minimize respondent burden.

Follow-up telephone assessments were completed at 3, 6, 12, and 18 months after randomization by research assistants who were not masked to treatment assignment but did not provide any form of intervention. Participants were offered a \$25 incentive for the completion of each survey and a \$20 bonus for completing all 4 surveys. Participants unreachable by telephone were offered \$15 for completing the survey via the Internet.

The study outcome metric was 30-day PPA determined at each follow-up in accordance with guidelines from the Society for Research on Nicotine and Tobacco.<sup>31</sup> Because no specific quit date was set in advance for study participants, the traditional conservative measure of continuous abstinence starting at a fixed quit date could not be used. However, we constructed a measure of sustained abstinence by combining 30-day multiple PPA reports at 3, 6, 12, and 18 months. In these analyses, an individual was coded as an abstainer at a particular follow-up if he or she reported 30-day PPA at 3 months and at all subsequent time points up to the one being measured. We report 30-day single and multiple PPA rates at each follow-up point.

## STATISTICAL ANALYSES

The distributional properties of continuously scaled variables were examined to determine the need for normalizing transformations. Next, we examined whether there were any pretreatment group differences on demographic, psychosocial, and smoking characteristics of study participants using analysis of variance–based *F* tests for continuous variables and  $\chi^2$  tests for categorical variables. At each time point, we modeled follow-up assessment completion as a function of treatment group and baseline covariates using the entire sample to identify participant characteristics predictive of missingness.

Abstinence rates were analyzed using generalized estimating equation methods with a working independence correlation matrix. Naive *P* values for pairwise differences reported by logistic regression were corrected using robust standard errors reported by PROC GENMOD of SAS/STAT statistical software, version 9.1.3 (SAS Institute Inc, Cary, North Carolina). Omnibus  $\chi^2$  tests of any between-group differences at each of the 4 follow-ups were based on multivariate Wald tests conducted at a multiplicity-adjusted significance level  $\alpha = .05/4$ . Following the Fisher least significant difference procedure for controlling the familywise error rate in 3-group comparisons, findings of significant between-group differences at a particular follow-up were followed by examination of all pairwise contrasts at an unadjusted 2-sided significance level of  $\alpha = .05$ . Our primary analysis was based on an intent-to-treat (ITT) approach in which individuals lost to follow-up were treated as smokers. A responder-only analysis of only those reached at follow-up is also pre-

sented for comparison purposes. For multiple PPA analyses, the responder-only sample at each time point was limited further to individuals with no missing data at prior follow-ups.

## RESULTS

The **Figure** illustrates the flow of participants from recruitment through follow-up using a CONSORT diagram. Of the 99 831 individuals invited to participate, most (62.2%) were recruited from Google, 22.3% from Yahoo!, 13.5% from MSN, and 2.0% from America Online. Invited participants used common search terms such as *quit smoking* (45.4%), *stop smoking* (19.7%), *smoking* (15.1%), and *quitting smoking* (11.6%).

Characteristics of the 2005 participants randomized to treatment are given in **Table 1**. Mean (SD) age was 35.9 (10.8) years, and 51.1% were women. Recruitment of racial/ethnic minorities was largely successful, matching US proportions of smokers for all subgroups except Hispanics and African American men.<sup>32</sup> There were no significant differences on any demographic, smoking, or psychosocial variables assessed at baseline among the 3 treatment groups (all *P* > .15).

## FOLLOW-UP RATES AND PREDICTORS OF FOLLOW-UP COMPLETION

Follow-up rates at 3, 6, 12, and 18 months after randomization were 76.4%, 74.7%, 71.5%, and 68.2%, respectively. Continuous follow-up rates relevant to multiple PPA responder-only analyses were 76.4%, 66.8%, 59.4%, and 54.1%, respectively. At 3 months, fewer participants in the EI+P group were reached than in the BI group (73.5% vs 79.1%, *P* = .02), a discrepancy that affected continuous follow-up rates at all subsequent time points as well. There were no other treatment group differences in follow-up completion rates at any time point. We also examined treatment group differences in the proportion of participants who responded via telephone vs Internet survey. Over time, an increasingly larger proportion of participants responded via the Internet: 3-, 6-, 12-, and 18-month Internet survey response rates were 6.9%, 12.4%, 14.6%, and 15.4%, respectively. There were no differences among the treatment groups in mode of follow-up response except at 18 months, with more respondents via Internet survey in the EI+P group (19.2%) than in the other 2 treatment conditions (13.5% in the BI group and 13.4% in the EI group, *P* = .02).

Participant characteristics at baseline positively associated with follow-up assessment completion at all 4 time points included older age, female sex, and graduation from a 4-year college. High level of diversity of social network connections was related to follow-up assessment completion at 3 months. In addition, white race, lower nicotine dependence levels as measured by the Fagerström Test for Nicotine Dependence, and positive balance in partner interactions as measured by the difference between positive and negative subscales of the Partner Interaction Questionnaire emerged as additional predictors of follow-up completion at 12 and 18 months.




Figure. CONSORT (Consolidated Standards of Reporting Trials) diagram of participants.

## OUTCOME ANALYSES

**Table 2** displays self-reported 30-day single PPA rates by treatment group during the study. In the ITT samples, abstinence rates ranged from 9.1% to 19.0% at 3 months and increased to a range of 17.4% to 19.6% at 18 months. In the responder-only sample, abstinence rates ranged from 11.6% to 25.9% at 3 months and increased to a range of 25.2% to 29.1% at 18 months. Between-group differences significant at level  $\alpha = .05/4$  were observed at 3, 6, and 12 months but not at 18 months. In ITT analyses, post hoc comparisons showed EI+P outperforming the other conditions at 3 and 6 months (all  $P < .01$ ) and EI at 12 months ( $P = .003$ ). In responder-only analyses, EI+P outperformed the other conditions at 3, 6, and 12 months

(all  $P < .02$ ). The difference between EI and BI was not statistically significant at any time point under either set of analyses ( $P > .12$ ).

**Table 3** displays self-reported 30-day multiple PPA rates by treatment group during the study. Unlike single PPA rates that showed especially pronounced increases over time for the BI and EI groups, multiple PPA rates decreased over time. In the ITT sample, multiple PPA rates ranged from 9.1% to 19.0% at 3 months and decreased to a range of 3.5% to 7.7% at 18 months. In the responder-only sample, multiple PPA rates ranged from 11.6% to 25.9% at 3 months and decreased to a range of 6.2% to 15.0% at 18 months. Overall between-group differences significant at level  $\alpha = .05/4$  were observed at all time points. In ITT analyses, post hoc comparisons showed EI+P out-

**Table 1. Baseline Characteristics of Participants**

Variable	No. (%) of Participants <sup>a</sup>
<b>Demographic</b>	
Age, mean (SD), y	35.9 (10.8)
Women	1024 (51.1)
Education, highest grade completed	
Grade 1-11	63 (3.1)
Grade 12 or general educational development degree	381 (19.0)
College, 1-3 y	947 (47.2)
College, ≥4 y	614 (30.6)
Race	
White	1735 (86.5)
African American	173 (8.6)
Asian	62 (3.1)
Native Hawaiian/other Pacific Islander	8 (0.4)
American Indian/Alaska Native	27 (1.4)
Hispanic ethnicity	81 (4.0)
Annual income, \$ <sup>b</sup>	
<30 000	565 (28.3)
30 000 to <50 000	567 (28.4)
50 000-75 000	400 (20.1)
>75 000	462 (23.2)
Marital status <sup>b</sup>	
Married	814 (40.6)
Cohabiting	309 (15.4)
Single	405 (20.2)
Separated	74 (3.7)
Divorced	381 (19.0)
Widowed	20 (1.0)
Employment status <sup>b</sup>	
Full time	1430 (71.4)
Part time	187 (9.3)
Unemployed	111 (5.5)
Homemaker	91 (4.5)
Retired	42 (2.1)
Student	142 (7.1)
<b>Smoking</b>	
Age at first puff, mean (SD), y	14.21 (3.73)
Age at onset of daily smoking, mean (SD), y	17.19 (3.86)
Daily smoking rate, mean (SD)	20.00 (9.96)
No. of quit attempts in past year, mean (SD) <sup>b</sup>	3.27 (8.00)
Baseline stage of change	
Precontemplation	2 (0.1)
Contemplation	235 (11.7)
Preparation	1768 (88.2)
Fagerström Test for Nicotine Dependence score, mean (SD) <sup>b</sup>	5.04 (2.37)
Desire to quit, mean (SD)	9.08 (1.29)
Confidence in quitting, mean (SD) <sup>b</sup>	6.28 (2.25)
<b>Psychosocial</b>	
Perceived Stress Scale score, mean (SD) <sup>b</sup>	6.16 (3.23)
Center for Epidemiologic Studies–Depression Scale score, mean (SD)	9.23 (5.79)
Social Network Index scores	
Network diversity, mean (SD) <sup>b</sup>	5.41 (1.83)
No. of network members, mean (SD) <sup>b</sup>	22.60 (16.91)
Partner Interaction Questionnaire scores <sup>b</sup>	
Positive subscale	9.79 (2.32)
Negative subscale	6.04 (4.22)
Subscale difference, positive-negative	3.75 (4.49)

<sup>a</sup>Data are presented as number (percentage) of participants (n=2005) unless otherwise indicated. There were no statistically significant differences among treatment groups on any of the variables examined (all  $P > .15$ ).

<sup>b</sup>Participants were able to refuse answering a question or respond "don't know." Sample sizes were as follows: income, 1994; marital status, 2003; employment status, 2003; number of quit attempts, 1999; Fagerström Test of Nicotine Dependence, 1989; confidence in quitting, 2004; perceived stress scale, 2004; network diversity, 1989; and number of network members, 1995.

performing the other conditions at 3, 6, 12, and 18 months (all  $P < .02$ ). Responder-only analyses reached the same conclusions (all  $P < .005$ ). The difference between EI and BI was not statistically significant at any time point under either set of analyses (all  $P > .30$ ).

### COMMENT

This large-scale randomized trial evaluated Internet only and Internet plus telephone treatment for smoking cessation with encouraging short- and long-term cessation outcomes. The conservative measure of multiple PPA favored the EI + P condition throughout the follow-up time points, likely reflecting initial, sustained gains. Significant between-group differences in the more commonly reported 30-day PPA rates during the first 12 months of the study were driven by superior outcomes in the EI + P condition achieved early in the study period and maintained over time. The addition of telephone counseling significantly increased cessation at 3 and 6 months over the 2 Internet conditions, although these differences were eventually attenuated at 18 months because of improvement in the BI and EI conditions.

This study has several strengths. Designed largely as a pragmatic randomized trial,<sup>33</sup> the study sought to maximize generalizability and real-world relevance while preserving internal validity. The use of a recruitment method to obtain a representative sample of the Internet population entirely in vivo, in this case in the moment of searching online for information about cessation, is innovative and demonstrates the feasibility of conducting large-scale randomized trials via the Internet. It is one of the few randomized trials of a widely disseminated Internet cessation intervention that will advance the science of Internet research.<sup>21</sup> The study evaluates treatments as used in the real world, bridging what is often a critical gap between tightly controlled clinical research and the applicability of research findings in practice.<sup>34</sup> The interventions are practical, can be scaled up to meet demand, and can be combined with other modalities of intervention provision (eg, primary care, managed care, and work site). These results extend and are consistent with the uncontrolled study of Internet and telephone treatment by Zbikowski et al.<sup>13</sup> Triage of smokers via the Internet may represent an effective and efficient way to provide combined cessation treatment to a large number of smokers, of whom approximately 20% can be expected to quit.

It is noteworthy that EI + P treatment yielded relatively high quit rates early in the study (19% at 3 months), which were observed over time. The integration of Internet and telephone programs may encourage greater immediate use and adherence to the information and support available through both modalities, may prevent early relapse by virtue of the timing of the counseling calls, and/or may provide direct social support that allows the counselor to tailor the intervention to the smoker's needs. The specific contribution of telephone counseling to the higher level of success of the combined program over each of the Internet-only interventions is unclear. It is possible that telephone counseling encouraged participants to set an early quit date and helped them sustain that early quit. Future

**Table 2. Thirty-Day Single Point Prevalence Abstinence Rates for ITT and Responder-Only Samples**

Follow-up	Group			Between-Group Comparisons <sup>a</sup>			
	BI	EI	EI + P	All	BI vs EI	BI vs EI + P	EI vs EI + P
3 mo							
No. <sup>b</sup>	62	68	128	...	...	...	...
ITT, %	9.1	10.4	19.0	<.001	.42	<.001	<.001
Responders, %	11.6	13.6	25.9	<.001	.31	<.001	<.001
6 mo							
No. <sup>b</sup>	83	94	133	...	...	...	...
ITT, %	12.2	14.4	19.7	<.001	.23	<.001	.01
Responders, %	15.8	19.5	27.3	<.001	.12	<.001	.004
12 mo							
No. <sup>b</sup>	119	98	145	...	...	...	...
ITT, %	17.5	15.1	21.5	.009	.22	.07	.003
Responders, %	24.2	20.9	30.8	.002	.23	.02	<.001
18 mo							
No. <sup>b</sup>	129	113	132	...	...	...	...
ITT, %	19.0	17.4	19.6	.57	.44	.80	.30
Responders, %	27.9	25.2	29.1	.39	.35	.67	.18

Abbreviations: BI, basic Internet; EI, enhanced Internet; EI + P, enhanced Internet and telephone counseling; ellipses, not applicable; ITT, intent to treat.

<sup>a</sup>P values are listed for omnibus test and pairwise comparisons.

<sup>b</sup>Number of individuals per group who achieved 30-day point prevalence abstinence.

**Table 3. Thirty-Day Multiple Point Prevalence Abstinence Rates for the Designated Follow-up and All Preceding Intervals**

Follow-up	Group			Between-Group Comparisons <sup>a</sup>			
	BI	EI	EI + P	All	BI vs EI	BI vs EI + P	EI vs EI + P
3 mo							
No. <sup>b</sup>	62	68	128	...	...	...	...
ITT, %	9.1	10.4	19.0	<.001	.42	<.001	<.001
Responders, %	11.6	13.6	25.9	<.001	.31	<.001	<.001
6 mo							
No. <sup>b</sup>	45	48	84	...	...	...	...
ITT, %	6.6	7.4	12.4	<.001	.59	<.001	.002
Responders, %	9.4	11.0	19.8	<.001	.41	<.001	<.001
12 mo							
No. <sup>b</sup>	31	31	64	...	...	...	...
ITT, %	4.6	4.8	9.5	<.001	.87	<.001	.004
Responders, %	7.3	7.9	17.2	<.001	.75	<.001	<.001
18 mo							
No. <sup>b</sup>	24	29	52	...	...	...	...
ITT, %	3.5	4.5	7.7	.002	.39	.001	.02
Responders, %	6.2	8.2	15.0	<.001	.30	<.001	.005

Abbreviations: BI, basic Internet; EI, enhanced Internet; EI + P, enhanced Internet and telephone counseling; ellipses, not applicable; ITT, intent to treat.

<sup>a</sup>P values are listed for omnibus test and pairwise comparisons.

<sup>b</sup>Number of individuals per group who achieved 30-day point prevalence abstinence for the designated follow-up and all preceding intervals.

studies will need to explore the optimum dose and format of adjuvant telephone treatment, as well as the mechanisms of action. The equivalent performance of EI and BI in this trial is consistent with other studies that found no significant differences between static and interactive Web sites.<sup>5,6,10</sup> Identifying the active ingredients and optimal levels of intensity and tailoring of Internet cessation programs will be an important next step for the field. Future research should address this issue, perhaps with the use of adaptive research methods to ensure that interventions continue to improve as technology, consumer expectations, and scientific understanding advance.

Several limitations should be noted. In designing this study, one might have considered other comparison or no-

treatment control conditions, especially in light of the unexpectedly high long-term quit rates in the information-only BI condition. However, the selection of an appropriate control condition raises pragmatic, ethical, and methodologic challenges that are not easy to resolve.<sup>21</sup> Because participants were recruited online from within a search engine query, a basic information Web site (minimum treatment control) condition was deemed the best option. We considered using or adapting to an online format a self-help manual commonly used as a minimal treatment control in smoking studies but determined that it would lack important qualities of usability, credibility, and interactivity that Internet users expect. The relatively high abstinence rates observed in the BI condition should be considered in the context of the recruit-

ment approach, which may have self-selected participants with unusually high motivation to quit. Although recruitment was conducted from a real-world sample of smokers on the Internet and data were collected on enrollees and nonenrollees,<sup>17</sup> generalizability is limited to that sample frame. As a related issue, it is possible that a bias against using a telephone intervention exists among individuals who turn to the Internet for smoking cessation assistance. The lower follow-up assessment rate among EI+P participants at 3 months may have been owing to “telephone fatigue” among Internet users randomized to receive proactive telephone counseling. Telephone counseling was provided within the first 3 months of the study, which was the only assessment period for which higher loss to follow-up was observed. If present, this bias could have attenuated the effectiveness of the combined intervention. Future research will need to determine the extent to which recruitment modality (ie, Internet vs telephone) affects treatment preference, use, and outcomes.

Despite these caveats, the potential public health significance (impact = reach × efficacy<sup>35</sup>) of these findings is striking. Combining evidence-based cessation interventions such as Internet and telephone counseling could substantially accelerate cessation in the United States.<sup>16,36</sup> The broad reach of the Internet to more than 10 million smokers seeking assistance each year<sup>2</sup> and the ubiquitous use of telephones, combined with the efficacy demonstrated in this study (7.7%–19.6% quit at 18 months), suggests that the potential population impact of this treatment approach is high.

In conclusion, our findings demonstrate the effectiveness of combined Internet and telephone treatment for smoking cessation in promoting sustained abstinence, as well as the effectiveness of BI and EI treatments, which accumulates during longer periods. Future studies will need to address the optimal duration, intensity, and active ingredients of treatment and assess the cost-effectiveness of these potentially widely disseminable interventions.

**Accepted for Publication:** June 16, 2010.

**Correspondence:** Amanda L. Graham, PhD, Schroeder Institute for Tobacco Research and Policy Studies, American Legacy Foundation, 1724 Massachusetts Ave NW, Washington, DC 20036 (agraham@americanlegacy.org).

**Author Contributions:** Drs Graham, Papandonatos, Bock, and Abrams had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Graham, Cobb, Papandonatos, Tinkelman, Bock, Niaura, and Abrams. *Acquisition of data:* Graham, Moreno, Tinkelman, and Cobb. *Analysis and interpretation of data:* Graham, Cobb, Papandonatos, Moreno, Kang, Tinkelman, Bock, Niaura, and Abrams. *Drafting of the manuscript:* Graham, Cobb, Papandonatos, Tinkelman, Bock, Niaura, and Abrams. *Statistical analysis:* Graham, Cobb, Papandonatos, Moreno, and Kang. *Obtained funding:* Graham and Abrams. *Administrative, technical, or material support:* Moreno and Kang. *Study supervision:* Graham, Cobb, and Tinkelman.

**Financial Disclosure:** Dr Cobb is a consultant to Healthways Inc, the current owner of the QuitNet system. Dr Niaura has received honoraria/consulting fees and/or served on speaker bureaus for GlaxoSmithKline plc, Pfizer Inc, sanofi-aventis LLC, and Novartis Pharmaceuticals.

**Funding/Support:** This research was funded by grant R01-CA104836 from the National Cancer Institute of the National Institutes of Health.

**Role of the Sponsor:** The funding agency had no role in the study design, analysis, interpretation of data, decision regarding publication, or preparation of this article.

## REFERENCES

1. Institute of Medicine. *Ending the Tobacco Problem: A Blueprint for the Nation*. Washington, DC: The National Academies Press; 2007.
2. Fox S. *Online Health Search 2006*. Washington, DC: Pew Internet and American Life Project; 2006.
3. Cobb NK, Graham AL. Characterizing Internet searchers of smoking cessation information. *J Med Internet Res*. 2006;8(3):e17. doi:10.2196/jmir.8.3.e17.
4. Fiore MC, Jaen CR, Baker TB, et al. *Treating Tobacco Use and Dependence: 2008 Update: Clinical Practice Guideline*. Rockville, MD: US Department of Health and Human Services; 2008.
5. Pike KJ, Rabinus V, McAlister A, Geiger A. American Cancer Society's QuitLink: randomized trial of Internet assistance. *Nicotine Tob Res*. 2007;9(3):415-420.
6. Rabinus V, Pike KJ, Wiatrek D, McAlister AL. Comparing Internet assistance for smoking cessation: 13-month follow-up of a six-arm randomized controlled trial. *J Med Internet Res*. 2008;10(5):e45. doi:10.2196/jmir.1008.
7. Strecher VJ, McClure JB, Alexander GL, et al. Web-based smoking-cessation programs: results of a randomized trial. *Am J Prev Med*. 2008;34(5):373-381.
8. Strecher VJ, McClure J, Alexander G, et al. The role of engagement in a tailored Web-based smoking cessation program: randomized controlled trial. *J Med Internet Res*. 2008;10(5):e36. doi:10.2196/jmir.1002.
9. Swartz LHG, Noell JW, Schroeder SW, Ary DV. A randomized control study of a fully automated internet based smoking cessation programme. *Tob Control*. 2006; 15(1):7-12.
10. Muñoz RF, Barrera AZ, Delucchi K, Penilla C, Torres LD, Pérez-Stable EJ. International Spanish/English Internet smoking cessation trial yields 20% abstinence rates at 1 year. *Nicotine Tob Res*. 2009;11(9):1025-1034.
11. Walters ST, Wright JA, Shegog R. A review of computer and Internet-based interventions for smoking behavior. *Addict Behav*. 2006;31(2):264-277.
12. Myung S-K, McDonnell DD, Kazinets G, Seo HG, Moskowitz JM. Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. *Arch Intern Med*. 2009;169(10):929-937.
13. Zbikowski SM, Hapgood J, Smucker Barnwell S, McAfee T. Phone and web-based tobacco cessation treatment: real-world utilization patterns and outcomes for 11,000 tobacco users. *J Med Internet Res*. 2008;10(5):e41. doi:10.2196/jmir.999.
14. Cummins SE, Bailey L, Campbell S, Koon-Kirby C, Zhu S-H. Tobacco cessation quitlines in North America: a descriptive study. *Tob Control*. 2007;16(suppl 1):i9-i15. doi:10.1136/tc.2007.020370.
15. Croyle RT. Increasing the effectiveness of tobacco quitlines. *J Natl Cancer Inst*. 2010;102(2):72-73.
16. Abrams DB, Graham AL, Levy DT, Mabry PL, Orleans CT. Boosting population quits through evidence-based cessation treatment and policy. *Am J Prev Med*. 2010;38(3)(suppl):S351-S363.
17. Graham AL, Bock BC, Cobb NK, Niaura R, Abrams DB. Characteristics of smokers reached and recruited to an internet smoking cessation trial: a case of denominators. *Nicotine Tob Res*. 2006;8(suppl 1):S43-S48.
18. Cobb NK, Graham AL, Abrams DB. Social network structure of a large online community for smoking cessation. *Am J Public Health*. 2010;100(7):1282-1289.
19. Zhu S-H, Stretch V, Balabanis M, Rosbrook B, Sadler G, Pierce JP. Telephone counseling for smoking cessation: effects of single-session and multiple-session interventions. *J Consult Clin Psychol*. 1996;64(1):202-211.
20. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. *Addiction*. 2004;99(1):29-38.
21. Danaher BG, Seeley JR. Methodological issues in research on web-based behavioral interventions. *Ann Behav Med*. 2009;38(1):28-39.
22. Centers for Disease Control and Prevention. *2002 Behavioral Risk Factor Surveillance System—Survey Questions*. Atlanta, GA: Centers for Disease Control and Prevention; 2002.
23. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive behaviors. *Am Psychol*. 1992;47(9):1102-1114.
24. Heatheron TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addict*. 1991;86(9):1119-1127.
25. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds. *The Social Psychology of Health: Claremont Symposium on Applied Social Psychology*. Newbury Park, CA: Sage Publications; 1988.
26. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*. 1983;24(4):385-396.
27. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression

- in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med.* 1994;10(2):77-84.
28. Graham AL, Papandonatos GD, Bock BC, et al. Internet- vs telephone-administered questionnaires in a randomized trial of smoking cessation. *Nicotine Tob Res.* 2006;8(suppl 1):S49-S57.
  29. Cohen S, Doyle WJ, Skoner DP, Rabin BS, Gwaltney JM Jr. Social ties and susceptibility to the common cold. *JAMA.* 1997;277(24):1940-1944.
  30. Cohen S. Social supports and physical health. In: Greene A, Cummings M, Karraker K, eds. *Life-Span Developmental Psychology: Perspectives on Stress and Coping.* Hillsdale, NJ: Erlbaum Associates; 1991.
  31. Hughes JR, Benowitz N, Hatsukami D, Mermelstein RJ, Shiffman S. Clarification of SRNT workgroup guidelines for measures in clinical trials of smoking cessation therapies. *Nicotine Tob Res.* 2004;6(5):863-864.
  32. National Center for Health Statistics National Health Interview Survey, 2007. [http://www.cdc.gov/nchs/nhis/quest\\_data\\_related\\_1997\\_forward.htm](http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm). Accessed March 23, 2009.
  33. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *CMAJ.* 2009;180(10):E47-E57. doi:10.1503/cmaj.090523.
  34. Green LW, Glasgow RE. Evaluating the relevance, generalization, and applicability of research: issues in external validation and translation methodology. *Eval Health Prof.* 2006;29(1):126-153.
  35. Abrams DB, Orleans CT, Niaura RS, Goldstein MG, Prochaska JO, Velicer W. Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: a combined stepped-care and matching model. *Ann Behav Med.* 1996;18(4):290-304.
  36. Levy DT, Graham AL, Mabry PL, Abrams DB, Orleans CT. Modeling the impact of smoking-cessation treatment policies on quit rates. *Am J Prev Med.* 2010;38(3)(suppl):S364-S372.

## INVITED COMMENTARY

# Integrating Comprehensive Tobacco Treatment Into the Evolving US Health Care System

## *It's Time to Act*

**T**obacco use remains the leading preventable cause of death in the United States, contributing to unsustainable health care costs and unacceptable socioeconomic disparities in disease burden.<sup>1</sup> Clearly, treating tobacco use and dependence should be a high priority for physicians and for all those who organize, provide, and pay for health care. Unfortunately, this is not the case. Despite its recognition as a chronic disease,<sup>2</sup> the availability of therapies that are among the most cost-effective in health care,<sup>3</sup> and evidence-based clinical guidelines,<sup>4</sup> tobacco dependence has not been treated with the respect and attention it deserves by the US health care system.<sup>1</sup>

## *See also page 39*

As health care provision evolves in the era of health care system reform, how can we ensure that tobacco dependence treatment is no longer neglected? How can we integrate tobacco treatment into the newly envisioned systems for providing and paying for health care, from ambulatory-based, patient-centered medical homes and neighborhoods to more comprehensive integrated health care provision systems such as accountable care organizations?

A substantial body of evidence indicates that we need a comprehensive care management system for tobacco dependence similar to the systems being used to manage other chronic diseases.<sup>4,5</sup> A tobacco care management system should look like this:

- The tobacco use status of every patient encountered in any setting (inpatient and outpatient, primary and specialty care) is routinely assessed and recorded in a way that allows easy identification of a registry of tobacco users (ie, all the tobacco users for whom a health care professional, practice, or health care organization is responsible).

- Every tobacco user who presents for care is routinely advised to quit, briefly offered appropriate evidence-based tobacco treatment (including Food and Drug Administration [FDA]-approved pharmacotherapy), and automatically linked to affordable resources in the health care system or community that supplement the health care professional's brief visit-based effort. Such resources would include counseling and medication management provided in person, by telephone, or via the Internet.

- Visit-based care is supplemented with "direct-to-smoker" outreach from the practice or health care system that offers treatment to the entire population of smokers for whom the organization is responsible.

- Treatment is coordinated centrally across sites of care and over time.

- Evidence-based tobacco dependence treatment, including counseling and medication, is reimbursed without constraints that limit access to care, such as preauthorization and substantial copayments. Coverage policies should recognize the relapsing nature of tobacco dependence and allow for multiple courses or long-term use of all FDA-approved medications, including nonprescription nicotine replacement products.

- A health care system's performance in providing tobacco treatment to patients (and eventually in achieving the outcome of tobacco use cessation) is routinely monitored as a quality indicator, reported back to the system, and publicly reported.

To build this system, models of treatment demonstrated to be efficacious in research settings must be adapted to fit into real-world health care provision and reimbursement structures. The care of smokers after an acute myocardial infarction (MI) is a good example. These patients benefit more rapidly and substantially from quitting than any other group of smokers.<sup>6</sup> The efficacy of initiating tobacco treatment during a hospital stay for MI

Overall, there seems to be no major difference between the individual drug classes as to total or cardiovascular disease mortality,<sup>6,8</sup> and this holds true even when looking at high-risk (diabetic) patients.<sup>9</sup> Then again, the risk of renal cell carcinoma seems to be lower with diuretic therapy compared with other treatments, with the effect being less pronounced in women than in men.<sup>10</sup> In the light of the results by Sciarretta et al, we should therefore concentrate once again on the true center of medical attention—our patient—and we should weigh our choice of first-line treatment against comorbidities, coexisting treatment, and personal preferences regarding risk and quality of life.

Lutz Frankenstein, MD

**Author Affiliation:** Department of Cardiology, Angiology, and Pulmonology, University of Heidelberg, Heidelberg, Germany.

**Published Online:** November 8, 2010.  
doi:10.1001/archinternmed.2010.414

**Correspondence:** Dr Frankenstein, Department of Cardiology, Angiology, and Pulmonology, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany (Lutz.Frankenstein@med.uni-heidelberg.de).

**Financial Disclosure:** None reported.

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. *JAMA*. 1996;275(20):1557-1562.
2. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. *Hypertension*. 2009;54(5):1084-1091.
3. Turnbull F, Woodward M, Neal B, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? results of prospectively designed overviews of randomized trials. *Eur Heart J*. 2008;29(21):2669-2680.
4. Turnbull F, Neal B, Ninomiya T, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ*. 2008;336(7653):1121-1123.
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665. doi:10.1136/bmj.b1665.
6. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362(9395):1527-1535.
7. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet*. 2010;375(9718):906-915.
8. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. *JAMA*. 2003;289(19):2534-2544.
9. Turnbull F, Neal B, Algert C, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*. 2005;165(12):1410-1419.
10. Corrao G, Scotti L, Bagnardi V, Segà R. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. *Curr Drug Saf*. 2007;2(2):125-133.

#### Correction

**Errors in Figure.** In the Original Investigation titled "A Randomized Trial of Internet and Telephone Treatment for Smoking Cessation" by Graham et al, published in the January 10 issue of the *Archives* (2011; 171[1]:46-53), errors occurred in the Figure on page 49. In that Figure, a portion of the content within the boxes was incorrectly formatted and contained a typesetting error. In each box in the Follow-up section of the Figure, "×12" should not appear, a large space should appear after the first line in each box, the line "Lost to follow-up" should be left-aligned with the line above it, with a small space in between, and the lines beneath "Lost to follow-up" should be indented. The article was corrected online.